Compare Novartis AG (NVS) vs SAP SE (SAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs SAP SE — how do they compare? Novartis AG trades at $142.74 (market cap $274.00B), while SAP SE trades at $215 (market cap $243.69B). The key difference: Novartis AG and SAP SE are close in size by market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and SAP SE for 118 Days on average.
| NVS | SAP | |
|---|---|---|
Market Cap | $274.00B | $243.69B |
Volume | 1,852,137 | 1,991,579 |
Sector | Health | Technology |
52-Week High | $168.62 | $280.46 |
52-Week Low | $121.80 | $146.38 |
Typical Hold Time | 82 Days | 118 Days |
Enterprise Value | $315.32B | $242.43B |
Dividend Yield | 3.31% | 1.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
SAP trades at $212.40, up 0.92% with a bullish technical signal. The company reported strong Q1 2026 earnings beat but missed Q2 expectations. Revenue grew to $36.8B in 2025 with robust 20.41% net margin. Analyst consensus is bullish with $241.80 price target, though recent news shows mixed sentiment about AI execution and competitive threats.
SAP presents a compelling growth story with strong cloud revenue momentum and AI integration, though execution risks and valuation concerns remain. The stock offers 14% upside to consensus target, supported by €10B buyback program through 2027. Key risks include ERP market competition and margin pressure from cloud transition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
